Economic Burden of High-Risk Localized and Locally Advanced Prostate Cancer in LATAM: Experts Perspective

Speaker(s)

Araujo L1, Tamayo C2, Góngora DS3, Meirelles IO4, Tabares MF5, Palma C6, López L7, Medina Y8, Rosas S8, de Oliveira R9
1Janssen-Cilag Farmacêutica Ltda, Sao Paulo, SP, Brazil, 2IQVIA LatAM, Bogotá, CUN, Colombia, 3IQVIA, Bogotá, CUN, Colombia, 4IQVIA, Real-World Insights, Brazil, Sao Paulo, Sao Paulo, Brazil, 5IQVIA Argentina, Buenos Aires, Argentina, 6IQVIA, Real World Analytic Solutions & Real World Insights, Guatemala, Guatemala, Guatemala, Guatemala, 7IQVIA, Real-World Insights, Mexico, Mexico City, EM, Mexico, 8Janssen Pharmaceutical Companies of Johnson & Johnson, Bogotá D.C, CUN, Colombia, 9Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil

Presentation Documents

OBJECTIVES: High-risk localized and locally advanced prostate cancer patients (LPC/LAPC) still present significant unmet needs, such as high disease recurrence. In LATAM, there is scarce evidence on the burden of this population. This study describes the resource use and direct costs of LPC/LAPC in Argentina, Brazil, Colombia, Dominican Republic and Mexico.

METHODS: following a pragmatic literature review, we conducted double-blinded, semi-structured, online interviews with 10 experts per country to collect resource use data. Participants were from public healthcare setting in all countries except for Brazil (private setting). Unit costs were obtained from official price lists and results reported according to treatment received.

RESULTS: 40 urologists and 10 oncologists were interviewed. In all countries, the preferred therapies were prostatectomy and radiotherapy+androgen deprivation (RTx+ADT), with the proportion varying across countries (prostatectomy: 31% to 84%; RTx+ADT: 5% to 39%). In the total annual cost of 1L, the average direct cost varied from 46k USD to 115.2k USD in Argentina, 20.6k USD to 77k USD in Brazil, 12.1k USD to 50.6k USD in Colombia, 17.2k USD to 70k USD in Dominican Republic, and 4.9k USD to 35.3k USD in Mexico, according to main treatment received. The average percentage of hospitalized patients also varied between countries and treatment received (1%-16%). The proportion of patients with recurrent disease in the first year of treatment varied from 8% to 35% across countries regardless of treatment type. The average direct costs of treatment and monitoring of recurrent disease ranged from 19.6k USD to 86.7k USD in Argentina, 9k USD to 102.8k USD in Brazil, 13.2k USD to 47.3k USD in Colombia, 18.7k USD to 36.9k USD in Dominican Republic, and 3.5k USD to 7.3k USD in Mexico.

CONCLUSIONS: despite treatments with curative intent, recurrent disease is still an unmet need, impacting the economic burden of LPC/LAPC patients.

Code

EE100

Topic

Economic Evaluation, Study Approaches

Topic Subcategory

Literature Review & Synthesis, Surveys & Expert Panels

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology